Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Abstract Antibody Drug Conjugate (ADC) is an emerging technology to overcome the
limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an …

Breast tumors generally consist of a diverse population of cells with varying gene expression
profiles. Breast tumor heterogeneity is a major factor contributing to drug resistance …

Interrogating biological systems is often limited by access to biological probes. The
emergence of “click chemistry” has revolutionized bioconjugate chemistry by providing facile …

In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …

Combining the selective targeting of tumor cells through antigen-directed recognition and
potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in …

Site-selective protein modification is of significant interest in chemical biology research, with
lysine residues representing a particularly challenging target. Whilst lysines are popular for …

Valine–citrulline linkers are commonly used as enzymatically cleavable linkers for antibody–
drug conjugates. While stable in human plasma, these linkers are unstable in mouse plasma …